Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Potent synergistic effects of dulaglutide and food restriction in prevention of olanzapine-induced metabolic adverse effects in a rodent model

K. Horska, J. Kucera, E. Drazanova, G. Kuzminova, P. Amchova, M. Hrickova, J. Ruda-Kucerova, S. Skrede

. 2024 ; 176 (-) : 116763. [pub] 20240527

Jazyk angličtina Země Francie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24013348

BACKGROUND: Antipsychotics are indispensable in the treatment of severe mental illneses, however adverse metabolic effects including diabetes, weight gain, dyslipidemia, and related cardiovascular morbidity are common, and current pharmacological strategies for their management are unsatisfactory. Glucagon-like 1 peptide receptor agonists (GLP-1 RAs) are approved for the treatment of type 2 diabetes and obesity hold promise for the management of antipsychotic-associated adverse metabolic effects. METHODS: To characterize the molecular effects and identify biomarkers for GLP-1 RA preventive treatment, Sprague-Dawley female rats were treated with long-acting formulations of the antipsychotic olanzapine and the GLP-1 RA dulaglutide for 8 days. A pair-feeding protocol evaluated the combined effects of dulaglutide and food restriction on an olanzapine-induced metabolic phenotype. Body weight and food consumption were recorded. Biochemical analysis included a lipid profile, a spectrum of gastrointestinal and adipose tissue-derived hormones, and fibroblast growth factor 21 serum levels. RESULTS: Olanzapine induced hyperphagia, weight gain, increased serum triglycerides and HDL cholesterol. Food restriction affected the OLA-induced phenotype but not serum markers. Dulaglutide led to a modest decrease in food intake, with no effect on weight gain, and did not reverse the OLA-induced changes in serum lipid parameters. Concomitant dulaglutide and food restriction resulted in weight loss, decreased feed efficiency, and lower total and HDL cholesterol. CONCLUSIONS: A combined strategy of dulaglutide and food restriction manifested a massive synergistic benefit. GLP-1RAs represent a promising strategy and deserve thorough future research. Our findings underline the potential importance of lifestyle intervention in addition to GLP-1 RA treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013348
003      
CZ-PrNML
005      
20240905133813.0
007      
ta
008      
240725e20240527fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.biopha.2024.116763 $2 doi
035    __
$a (PubMed)38805968
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Horska, Katerina $u Department of Pharmacology and Toxicology, Faculty of Pharmacy, Masaryk University, Brno, Czech Republic
245    10
$a Potent synergistic effects of dulaglutide and food restriction in prevention of olanzapine-induced metabolic adverse effects in a rodent model / $c K. Horska, J. Kucera, E. Drazanova, G. Kuzminova, P. Amchova, M. Hrickova, J. Ruda-Kucerova, S. Skrede
520    9_
$a BACKGROUND: Antipsychotics are indispensable in the treatment of severe mental illneses, however adverse metabolic effects including diabetes, weight gain, dyslipidemia, and related cardiovascular morbidity are common, and current pharmacological strategies for their management are unsatisfactory. Glucagon-like 1 peptide receptor agonists (GLP-1 RAs) are approved for the treatment of type 2 diabetes and obesity hold promise for the management of antipsychotic-associated adverse metabolic effects. METHODS: To characterize the molecular effects and identify biomarkers for GLP-1 RA preventive treatment, Sprague-Dawley female rats were treated with long-acting formulations of the antipsychotic olanzapine and the GLP-1 RA dulaglutide for 8 days. A pair-feeding protocol evaluated the combined effects of dulaglutide and food restriction on an olanzapine-induced metabolic phenotype. Body weight and food consumption were recorded. Biochemical analysis included a lipid profile, a spectrum of gastrointestinal and adipose tissue-derived hormones, and fibroblast growth factor 21 serum levels. RESULTS: Olanzapine induced hyperphagia, weight gain, increased serum triglycerides and HDL cholesterol. Food restriction affected the OLA-induced phenotype but not serum markers. Dulaglutide led to a modest decrease in food intake, with no effect on weight gain, and did not reverse the OLA-induced changes in serum lipid parameters. Concomitant dulaglutide and food restriction resulted in weight loss, decreased feed efficiency, and lower total and HDL cholesterol. CONCLUSIONS: A combined strategy of dulaglutide and food restriction manifested a massive synergistic benefit. GLP-1RAs represent a promising strategy and deserve thorough future research. Our findings underline the potential importance of lifestyle intervention in addition to GLP-1 RA treatment.
650    _2
$a zvířata $7 D000818
650    12
$a imunoglobuliny - Fc fragmenty $x farmakologie $7 D007141
650    12
$a glukagonu podobné peptidy $x analogy a deriváty $x farmakologie $7 D004763
650    12
$a olanzapin $x farmakologie $x škodlivé účinky $7 D000077152
650    12
$a potkani Sprague-Dawley $7 D017207
650    _2
$a ženské pohlaví $7 D005260
650    12
$a rekombinantní fúzní proteiny $x farmakologie $7 D011993
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a antipsychotika $x farmakologie $x škodlivé účinky $7 D014150
650    _2
$a přijímání potravy $x účinky léků $7 D004435
650    _2
$a receptor pro glukagonu podobný peptid 1 $x agonisté $x metabolismus $7 D000067757
650    _2
$a hmotnostní přírůstek $x účinky léků $7 D015430
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a benzodiazepiny $x farmakologie $x škodlivé účinky $7 D001569
650    _2
$a tělesná hmotnost $x účinky léků $7 D001835
650    _2
$a kalorická restrikce $x metody $7 D031204
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kucera, Jan $u Research Centre for Toxic Compounds in the Environment (RECETOX), Faculty of Science, Masaryk University, Brno, Czech Republic; Department of Physical Activities and Health, Faculty of Sports Studies, Masaryk University, Kamenice 5, Brno 62500, Czech Republic
700    1_
$a Drazanova, Eva $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Institute of Scientific Instruments of the Czech Academy of Sciences, Brno, Czech Republic
700    1_
$a Kuzminova, Gabriela $u Department of Pharmacology and Toxicology, Faculty of Pharmacy, Masaryk University, Brno, Czech Republic
700    1_
$a Amchova, Petra $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Hrickova, Maria $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Ruda-Kucerova, Jana $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. Electronic address: jkucer@med.muni.cz
700    1_
$a Skrede, Silje $u Department of Clinical Science, Faculty of Medicine, University of Bergen, Bergen, Norway/Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway; Section of Clinical Pharmacology, Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway
773    0_
$w MED00005486 $t Biomedicine & pharmacotherapy $x 1950-6007 $g Roč. 176 (20240527), s. 116763
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38805968 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133807 $b ABA008
999    __
$a ok $b bmc $g 2143268 $s 1225214
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 176 $c - $d 116763 $e 20240527 $i 1950-6007 $m Biomedicine & pharmacotherapy $n Biomed Pharmacother $x MED00005486
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Možnosti archivace